Table 1. Selected ERBB family mutations found in patients.

ERBB mutation	Principle tumor type (cBioPortal)	Drug sensitivity	Drug insensitivity	Acquired resistance
EGFR R108G/K	Glioma	preclinical: erlotinib [143]
EGFR A289D/I/N/T/V	Glioma	preclinical: erlotinib [143]
EGFR E709A/K/Q	NSCLC	preclinical: afatinib, neratinib [144]
EGFR exon 18 insertions/deletions	NSCLC	preclinical, clinical: afatinib, neratinib [144]
EGFR G719A/C/D/S	NSCLC	clinical: erlotinib, gefitinib, afatinib [145], [35]
EGFR exon 19 insertions/deletions	NSCLC	clinical: erlotinib, gefitinib, afatinib [146]
EGFR exon 20 insertions/deletions	NSCLC	preclinical: EGF816, AP32788 [36, 37]	clinical: afatinib, gefitinib, erlotinib [147],[148],[35]
EGFR S768G/I/T	NSCLC	clinical: afatinib, gefitinib, erlotinib [149], [35]
EGFR T790M	NSCLC	clinical: osimertinib [28]; preclinical: EA1045 and cetuximab [34]	clinical: afatinib [26, 27]	clinical: gefitinib, erlotinib, afatinib [18, 19]
EGFR C797S/Y	NSCLC	preclinical: EA1045 and cetuximab [34]		clinical: osimertinib [32, 33]
EGFR L858R	NSCLC	clinical: gefitinib, erlotinib, afatinib [10],[11]
EGFR L861Q/R	NSCLC, lung squamous	clinical: gefitinib, erlotinib, afatinib [145], [35]
ERBB2 D277G/H/V/Y	bladder	preclinical: lapatinib, afatinib [80]
ERBB2 S310F/Y	bladder, breast, esophagogastric, colorectal, lung, cervical	preclinical: trastuzumab, lapatinib, neratinib, afatinib [77, 79, 80, 90]; clinical: neratinib [103, 105]	preclinical: cetuximab, panitumumab [79]
ERBB2 R678Q	esophagogastric, colorectal, bladder	preclinical: lapatinib, afatinib, neratinib [77, 80]
ERBB2 L755S	breast, bladder, colorectal	preclinical: neratinib, afatinib [77, 112]; clinical: neratinib [98, 103, 105]	preclinical: trastuzumab, lapatinib, cetuximab, panitumumab [77, 79, 85, 112]	preclinical: lapatinib [112]
ERBB2 D769H/Y	breast, bladder, esophagogastric, colorectal	preclinical: trastuzumab, lapatinib, neratinib [77]; clinical: neratinib [103]
ERBB2 exon 20 insertions/deletions	NSCLC	preclinical: lapatinib, afatinib, neratinib, AP32788 [36, 73, 77, 82, 84, 93]; clinical: trastuzumab, afatinib, neratinib, dacomitinib [96, 100-103, 105] [150], [97]	preclinical: erlotinib, gefitinib [73, 82, 93]	clinical: osimertinib [29]
ERBB2 V777L	breast, colorectal, esophagogastric	preclinical: trastuzumab, lapatinib, neratinib [77, 79, 85] clinical: neratinib [91]	preclinical: cetuximab, panitumumab [79]
ERBB2 T798I/M	breast	preclinical: afatinib [91]	preclinical: trastuzumab, lapatinib, neratinib [85, 91, 111]	clinical: neratinib [91]
ERBB2 V842I	colorectal, breast, esophagogastric, endometrial	preclinical: trastuzumab, lapatinib, neratinib [77, 79]; clinical: neratinib [103]	preclinical: cetuximab, panitumumab [79]
ERBB2 L869R	breast	preclinical: neratinib, afatinib [91]; clinical: neratinib [92, 103, 105]	preclinical: lapatinib [91]
ERBB3 V855A	NSCLC	preclinical: pertuzumab and afatinib [128]
ERBB3 mutations	multiple tumor types		clinical: neratinib [105]
ERBB4 KD mutations	melanoma, esophagogastric, colorectal	preclinical: lapatinib [132]